Celgene Investor Relations Sec arquivamentos dkkoaje

Celgene Investor Relations Sec arquivamentos

14.02.2021

Wisecarver8131

The Investor Relations website contains information about Allogene Therapeutics's business for stockholders, potential investors, and financial analysts. Learn how Celgene, a global biopharmaceutical company, is committed to improving the lives of patients worldwide by delivering truly innovative and life-changing treatments. Explore the therapies for Hematology, Oncology, Inflammation and Immunology and the medical research to help people live longer, better, and healthier. Source: Celgene Corporation and Acceleron Pharma Inc. Celgene Corporation Investors: +1-908-673-9628 ir@celgene.com or Media: +1-908-673-2275 media@celgene.com Acceleron Pharma Inc. Investors: Todd James, IRC, (617) 649-9393 Vice President, Investor Relations and Corporate Communications or Media: Matt Fearer, (617) 301-9557 Director, Corporate Find the latest SEC Filings data for Celgene Corporation (CELG.RT) at Nasdaq.com.

Bristol-Myers Squibb Company (NYSE: BMY) today filed a new investor presentation with the Securities and Exchange Commission (SEC) in connection with

The Investor Relations website contains information about Jounce Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. Celgene announced it will combine with Bristol-Myers Squibb, creating an innovative global biopharma leader to expand our innovation capabilities in small molecule design, biologics/synthetic biologics, protein degradation, antibody engineering and cell therapy. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription.

83 Wooster Heights Road Danbury, Connecticut 06810 USA +1 203-448-4663 ir@iqvia.com. Andrew Markwick Senior Vice President, Investor Relations and Treasury

The Investor Relations website contains information about Celgene Corporation business for stockholders, potential investors, and financial analysts. See below for additional tax information for Celgene shareholders as a result of the acquisition: As noted in the related Form S-4, the exchange of shares of Celgene common stock for the merger consideration pursuant to the merger was a taxable transaction for U.S. federal income tax purposes. (1) as defined in the Form S-4 filed with the SEC on February 20, 2019 under the heading “Celgene Proposal I: Adoption of the Merger Agreement and Bristol Myers Squibb Proposal I: Approval of the Stock Issuance—Material U.S. Federal Income Tax Consequences” beginning on page 165. Celgene Corp /de/ is primarely in the business of pharmaceutical preparations. For financial reporting, their fiscal year ends on December 31st. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Celgene Corp /de/.

Bristol-Myers Squibb Company (NYSE: BMY) today filed a new investor presentation with the Securities and Exchange Commission (SEC) in connection with

“Financial Information” and subheading “SEC Filings” or by contacting Celgene’s Investor Relations Department at ir@celgene.com. Certain Information Regarding Participants Bristol-Myers Squibb, Celgene, and their respective directors and executive officers may be considered participants in the solicitation of proxies in connection

Further information relevant to the interpretation of adjusted financial measures, and reconciliations of these adjusted financial measures to the most comparable GAAP measures, may be found on Celgene's website at www.Celgene.com in the "Investor Relations" section. Celgene undertakes no obligation to publicly update any forward-looking

These products may not be approved and/or licensed in all countries where this website is accessible. For information about Celgene products and services in countries other than the U.S., please contact the local office (as listed under the Global Network). SEC Filings Group 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements Filing year - Any - 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 - bluebird and Celgene will share 50% of U.S. costs and profits - - bluebird to receive milestones and royalties on ex-U.S. sales - CAMBRIDGE, Mass. & SUMMIT, N.J.--(BUSINESS WIRE)--Mar. 28, 2018-- bluebird bio, Inc. (Nasdaq: BLUE) and Celgene Corporation (Nasdaq: CELG) today announced that the companies have entered into an agreement to co-develop and co-promote bb2121, an investigational SEC Filings Group 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements Filing year - Any - 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 … “Financial Information” and subheading “SEC Filings” or by contacting Celgene’s Investor Relations Department at ir@celgene.com. Certain Information Regarding Participants Bristol-Myers Squibb, Celgene, and their respective directors and executive officers may be considered participants in the solicitation of proxies in connection Information” and subheading “SEC Filings” or by contacting Celgene’s Investor Relations Department at ir@celgene.com. Certain Information Regarding Participants Bristol-Myers Squibb, Celgene, and their respective directors and executive officers may be considered participants in … Due to the pending transaction with Bristol-Myers Squibb, Celgene is not hosting a conference call in conjunction with its third-quarter 2019 earnings release and does not expect to do so for future quarters. Please direct any questions regarding this press release to Celgene Investor Relations or Celgene Communications. About Celgene